Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other physicians.
| NASDAQ: SNTS |
| Current Price: 3.71 |
| Change: -0.06 |
2/8/2010 10:53:19 PM EST
Quotes delayed 20 minutes.
|
|
12/30/2009
Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers' Diarrhea
12/22/2009
Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
12/14/2009
Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences Virtual Conference
|
Santarus is hiring skilled people like you. Join our team today!
